Engene Holdings Inc. shares rise 2.46% after-hours following Generation Bio's corporate presentation on T cell-driven autoimmune disease.

Engene Holdings Inc. rose 2.46% in after-hours trading. The company's stock price increase may be attributed to the recent news from Generation Bio, which is developing a new category of therapeutics to address the role of T cells in autoimmune diseases. The company's lead target/indication for the first program, MY25, is expected to have an IND in the second half of 2026, with a cash runway into the second half of 2027.